Cytotoxic and apoptotic activity of Satureja sahendica Bornm essential oil in MDA-MB-231 breast cancer and A549 lung cancer cells: in vitro evidence
3 Biotech · 2026-01 · 16 (1)
DOI: 10.1007/s13205-025-04656-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift 3 Biotech, online erschienen am 08.12.2025. Verfasst von Maryam Shiralizadeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science, Faculty of Science, University of Kurdistan, Sanandaj, Iran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Kurdistan.
Abstract (Originalsprache)
This study evaluated the anticancer potential of Satureja sahendica essential oil (SSEO) against MDA-MB-231 (breast cancer) and A549 (lung cancer) cell lines. The chemical composition of SSEO, determined by GC-MS, revealed thymol (57.11%) and γ-terpinene (25.27%) as the major constituents. The MTT assay demonstrated that SSEO induced concentration- and time-dependent cytotoxicity, with IC₅₀ values of 0.69 mg/mL (24 h) and 0.28 mg/mL (72 h) for MDA-MB-231 cells, and 0.59 mg/mL (24 h) and 0.37 mg/mL (72 h) for A549 cells. Apoptosis was identified as the primary mode of cell death, confirmed by acridine orange/ethidium bromide dual staining and Annexin V-FITC/propidium iodide flow cytometry. Flow cytometric analysis quantified early apoptosis, showing 41.2% of treated MDA-MB-231 cells and 35.5% of treated A549 cells in the Annexin V+/PI- quadrant. To elucidate the molecular basis of these effects, a comprehensive in silico analysis, incorporating target prediction, protein-protein interaction network, and gene ontology enrichment, was performed. This approach identified key cancer-related proteins, including MAPK14, PIM1, CTSD, TOP2A, PDK1, KIFC1, and NF-κB, as potential targets of the major SSEO constituents. Additionally, the cytotoxic effect of SSEO was evaluated on the normal L929 cell line, where IC₅₀ values of 1.082 mg/mL (24 h) and 0.89 mg/mL (72 h) were observed, indicating notably lower toxicity toward normal cells compared to cancer cells. Collectively, these findings demonstrate that SSEO exerts cytotoxic effects primarily through the induction of apoptosis in both breast and lung cancer cells, highlighting its potential as a complementary anticancer agent. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-025-04656-0.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Science, Faculty of Science, University of Kurdistan, Sanandaj, Iran.
- Bioinformatics Laboratory, Department of Biology, School of Sciences, Razi University, Kermanshah, Iran.
- Department of Biotechnology, Iranian Research Organization for Science and Technology, Tehran, 13353-5111 Iran.
- Department of Horticultural Science and Engineering, Research Center of Medicinal Plants Breeding and Development, University of Kurdistan, Sanandaj, Iran.
ORCID-Profile: Raheleh Shakeri
Förderung
- University of Kurdistan
Zitieren
APA
Shiralizadeh, M., Shakeri, R., Pouraghajan, K., Safavi, M., & Khorshidi, J. (2026). Cytotoxic and apoptotic activity of Satureja sahendica Bornm essential oil in MDA-MB-231 breast cancer and A549 lung cancer cells: in vitro evidence. 3 Biotech, 16(1). https://doi.org/10.1007/s13205-025-04656-0
Vancouver
Shiralizadeh M, Shakeri R, Pouraghajan K, Safavi M, Khorshidi J. Cytotoxic and apoptotic activity of Satureja sahendica Bornm essential oil in MDA-MB-231 breast cancer and A549 lung cancer cells: in vitro evidence. 3 Biotech. 2026;16(1). doi:10.1007/s13205-025-04656-0
BibTeX
@article{Shiralizadeh2026,
author = {Shiralizadeh, Maryam and Shakeri, Raheleh and Pouraghajan, Khadijeh and Safavi, Maliheh and Khorshidi, Jalal},
title = {Cytotoxic and apoptotic activity of Satureja sahendica Bornm essential oil in MDA-MB-231 breast cancer and A549 lung cancer cells: in vitro evidence},
journal = {3 Biotech},
year = {2026},
volume = {16},
number = {1},
doi = {10.1007/s13205-025-04656-0}
}
EUVIMED